Selz Capital LLC is a hedge fund headquartered in New York and managed by Bernard T. Selz since 2003. The fund offers investment advisory services regarding security portfolios of individuals, as well as small businesses. As of the end of the first quarter of 2015, Selz Capital has a diversified portfolio with 23% invested in the consumer discretionary sector, 21% in transports, 18% in energy and 13% in healthcare. The fund has a total of 61 positions valued at $596 million according to its latest 13F filing and its largest holdings are represented by Macquarie Infrastructure Company LLC (NYSE:MIC), Actavis plc (NYSE:ACT), and Air Lease Corp (NYSE:AL).
Even though most smaller investors believe that tracking 13F filings is a waste of time because they are filed with a delay of 45 days after the end of a calendar quarter, the results of our study prove the opposite. To be on the safe side, we used a delay of 60 days in our backtests that involved 13F filings between 1999 and 2012 and still managed to gain an annual alpha in the double digits. Moreover, since the official launch of our strategy in August 2012, we obtained returns of more than 137%, beating the S&P 500 Total Return Index by some 80 percentage points (see more details on how to beat the market by following 13Fs).
Selz Capital LLC boosted its stake in Macquarie Infrastructure Company LLC (NYSE:MIC) by 69% during the quarter to 999,703 shares, with a value of $82.30 million. A couple of months ago, RBC Capital and Oppenheimer raised their price targets on Macquarie Infrastructure Company LLC (NYSE:MIC) to $94.00 and $85.00 respectively. Aside from Selz Capital, Brenner West Capital Partners and Tiger Legatus Capital are two other shareholders of Macquarie Infrastructure Company LLC (NYSE:MIC) among the funds from our database.
Bernard Selz’s fund has added 25,000 shares to its stake in Actavis plc (NYSE:ACT), raising it to 134,000 shares valued at $39.88 million. Actavis plc (NYSE:ACT) is the most popular healthcare stock among the funds we track, the bullish sentiment being caused by the company’s substantial growth through a line of acquisitions that has transformed it into one of the largest pharmaceutical companies. Andreas Halvorsen’s Viking Global and Dan Loeb’s Third Point are also prominent investors with large positions in Actavis plc (NYSE:ACT), according to their latest 13F filings.